Abstract
Background: Cardiovascular diseases, especially ischemic heart disease and cardiometabolic disease, remain to be the leading cause of morbidity and mortality worldwide. Despite recent progress in diagnostic and therapeutic approaches, the incidence of cardiovascular disease is still rising. Therefore, alternative favorable treatment is urgently needed to rescue the fast growing numbers of patients.
Objective: Herein we aimed to review the relevant role and explore the possibility of SIRT1 as a promising target for protection of heart from ischemia/reperfusion injury and cardiometabolic diseases.
Results: The activation of SIRT1 participates in a variety of important metabolic and physiologic processes including stress resistance, metabolism, apoptosis and energy balance in heart ischemia injury and cardiometabolic disease.
Conclusion: Current medication targeting SIRT1 may represent a new therapeutic trend for the prevention of cardiovascular disease that is related to energy balance and metabolism.
Keywords: SIRT1, ischemia reperfusion injury, metabolic disease, heart, resveratrol, therapy, target.
Current Drug Targets
Title:SIRT1 as a Promising Novel Therapeutic Target for Myocardial Ischemia Reperfusion Injury and Cardiometabolic Disease
Volume: 18 Issue: 15
Author(s): Dong Han, Jinda Wang, Sai Ma, Yundai Chen and Feng Cao*
Affiliation:
- Department of Cardiology, Chinese PLA General Hospital, Beijing, 100853,China
Keywords: SIRT1, ischemia reperfusion injury, metabolic disease, heart, resveratrol, therapy, target.
Abstract: Background: Cardiovascular diseases, especially ischemic heart disease and cardiometabolic disease, remain to be the leading cause of morbidity and mortality worldwide. Despite recent progress in diagnostic and therapeutic approaches, the incidence of cardiovascular disease is still rising. Therefore, alternative favorable treatment is urgently needed to rescue the fast growing numbers of patients.
Objective: Herein we aimed to review the relevant role and explore the possibility of SIRT1 as a promising target for protection of heart from ischemia/reperfusion injury and cardiometabolic diseases.
Results: The activation of SIRT1 participates in a variety of important metabolic and physiologic processes including stress resistance, metabolism, apoptosis and energy balance in heart ischemia injury and cardiometabolic disease.
Conclusion: Current medication targeting SIRT1 may represent a new therapeutic trend for the prevention of cardiovascular disease that is related to energy balance and metabolism.
Export Options
About this article
Cite this article as:
Han Dong, Wang Jinda, Ma Sai, Chen Yundai and Cao Feng*, SIRT1 as a Promising Novel Therapeutic Target for Myocardial Ischemia Reperfusion Injury and Cardiometabolic Disease, Current Drug Targets 2017; 18 (15) . https://dx.doi.org/10.2174/1389450116666150630110529
DOI https://dx.doi.org/10.2174/1389450116666150630110529 |
Print ISSN 1389-4501 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-5592 |
Call for Papers in Thematic Issues
New drug therapy for eye diseases
Eyesight is one of the most critical senses, accounting for over 80% of our perceptions. Our quality of life might be significantly affected by eye disease, including glaucoma, diabetic retinopathy, dry eye, etc. Although the development of microinvasive ocular surgery reduces surgical complications and improves overall outcomes, medication therapy is ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Dietary Habits of Mongolian People, and Their Influence on Lifestyle-Related Diseases and Early Aging
Current Aging Science Reactive Oxygen Species Formation by Polymorphonuclear Cells and Mononuclear Cells as a Risk Factor of Cardiovascular Diseases
Current Pharmaceutical Biotechnology Efficacy of Adjunctive Brexpiprazole in Patients with Major Depressive Disorder: A Clinical Overview
Current Psychiatry Reviews Electrocardiographic and Cardiac Autonomic Indices - Implications of Sex-Specific Risk Stratification in Women After Acute Myocardial Infarction
Current Pharmaceutical Design Chronic Hepatitis C, Insulin Resistance and Vascular Disease
Current Pharmaceutical Design Synergistic Effect of Inhibitors of MMPs and ROS-dependent Modifications of Contractile Proteins on Protection Hearts Subjected to Oxidative Stress
Current Pharmaceutical Design Editorial [Hot Topic:Are the Pleiotropic Effects of Drugs Used for the Prevention of Cardiovascular Disease Clinically Relevant?(Executive Editors: M. Elisaf and E.N. Liberopoulos)]
Current Pharmaceutical Design Vertical and Horizontal Convergences of Targeting Pathways in Combination Therapy with Baicalin and Jasminoidin for Cerebral Ischemia
CNS & Neurological Disorders - Drug Targets Update on Anti-TNF-Alpha Treatment in Rheumatic Diseases
Current Drug Therapy Ignored Avenues in Alpha-Synuclein Associated Proteopathy
CNS & Neurological Disorders - Drug Targets The Role of Disproportionality Analysis of Pharmacovigilance Databases in Safety Regulatory Actions: a Systematic Review
Current Drug Safety Insulin Resistance and Polycystic Ovary Syndrome Through Life
Current Pharmaceutical Design Inflammatory Markers in Hyperlipidemia: From Experimental Models to Clinical Practice
Current Pharmaceutical Design Recent Advances in Endocrine Metabolic Immune Disorders Drug Targeting: An Editorial Overview
Endocrine, Metabolic & Immune Disorders - Drug Targets Circulating Biomarkers for the Diagnosis and Prognosis of Heart Failure
Current Medicinal Chemistry Patents in the Diagnosis and Therapy of Neurocardiogenic Syncope
Recent Patents on Cardiovascular Drug Discovery Current Options and Future Possibilities for the Treatment of Dyskinesia and Motor Fluctuations in Parkinson's Disease
CNS & Neurological Disorders - Drug Targets Recent Advances in Metabolomics
Current Metabolomics Management of Incidental Findings in the Era of Next-generation Sequencing
Current Genomics Direct Cardiac Reprogramming with Engineered miRNA Scaffolds
Current Pharmaceutical Design